Abstract

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

Is this guidance up to date?

Next review: June 2022

Commercial arrangements

There are simple discount patient access schemes for atezolizumab and bevacizumab. Contact welwyn.rx_bdop@roche.com for details.

Guidance development process

How we develop NICE technology appraisal guidance